Clascoterone 5% makes waves in male baldness treatment
Cosmo Pharmaceuticals just shared some big news: their new topical solution, clascoterone 5%, did well in the largest-ever Phase 3 trials for male pattern baldness.
Over 1,400 men across the US and Europe took part, testing either the real solution or a placebo for six months (with a six-month single-blind extension).
Noticeable results and a solid safety profile
Guys using clascoterone saw much more hair regrowth than those on placebo—up to five times better in one trial, and almost double in another.
Side effects were mild and actually happened less often with the treatment than with placebo.
What's next?
Cosmo plans to finish a year-long safety check by spring 2026 before asking health authorities like the FDA and EMA to approve clascoterone.
If all goes well, this could be the first new topical baldness treatment of its kind in over 30 years—a hopeful sign for anyone tired of hats or hiding their hairline.